ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Activity score"

  • Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium

    Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

    Suzanne Li1, Mara Becker 2, Sandy Hong 3, Polly Ferguson 4, Themba Nyrienda 5, Tracy Andrews 6, Katie Stewart 7, C. Egla Rabinovich 8, Robert Fuhlbrigge 9, Thomas Mason 10, Elena Pope 11, Maria Ibarra 12, Fatma Dedeoglu 13, Gloria Higgins 14, Ronald Laxer 15, Marilynn Punaro 16 and Kathryn Torok 17 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 3University of Iowa Stead Family Children's Hospital, Iowa City, 4University of Iowa Carver College of Medicine, Iowa City, 5Hackensack Univesity Medical Center, Hackensack, 6Rutgers University, Newark, 7UT Southwestern, Dallas, 8Duke University Hospital, Durham, 9University of Colorado, Aurora, 10Rochester, 11Hospital For Sick Kids, Toronto, Canada, 12Children's Mercy Kansas City, Kansas City, 13Boston Children's Hospital, Boston, 14Nationwide Childrens Hospital/ The Ohio State University, Columbus, 15The Hospital for Sick Children and University of Toronto, Toronto, Canada, 16Dallas, Texas, 17Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
  • Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting

    Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada

    Britney Jones1, Bo Pan 1, Joanne Homik 2, Anthony Russell 2, Walter P. Maksymowych 3, Jill Hall 1 and Stephanie Keeling 1, 1University of Alberta, Edmonton, AB, Canada, 2University of Alberta, Edmonton, Canada, 3University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

    Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
  • Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting

    Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

    MASAOMI YAMASAKI1, 1Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
  • Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting

    Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus

    Min-Hua Tseng1 and Jing-Long Huang2, 1Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2Medicine, Chang-Gung University, Taoyuan city, Taiwan

    Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…
  • Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
  • Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting

    Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort

    Manuel Ugarte-Gil1,2, Ines Segami3,4, Guillermina Harvey5, Guillermo J. Pons-Estel6, Rosana Quintana7, Cristina Reategui-Sokolova8, Jorge Cieza4, Luis J. Catoggio9, Mercedes Garcia10, Verónica Saurit11, Francisco Caeiro12, Cristina Drenkard13, Guillermo Berbotto14, Emilia Sato15, Lilian Costallat16, Eloisa Bonfa17, Joao C. Tavares Brenol18, Nilzio A Da Silva19, Fernando Cavalcanti20, Antonio Iglesias-Gamarra21, Marlene Guibert-Toledano22, Gil A. Reyes22, Loreto Massardo23, Oscar J Neira24, Mario H Cardiel25, Leonor Barile26, Mary Carmen Amigo27, Luis H. Silveira28, Ignacio Garcia de la Torre29, Eduardo Acevedo-Vasquez2, Rosa Chacón-Díaz30, Maria H Esteva Spinetti31, Graciela S. Alarcón32,33 and Bernardo A Pons-Estel7, 1Rheumatology, Universidad Científica del Sur, Lima, Peru, 2Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Universidad Nacional Mayor de San Marcos, Lima, Peru, 4Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, 5Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, 7Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, 8Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 9Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 10Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, 11Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 12Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 13Medicine/Rheumatology, Emory University, Atlanta, GA, 14Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, 15Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 16Universidade Estadual da Campinas, Campinas, Brazil, 17Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 18Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, 19Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, 20Universidade Federal da Pernambuco, Pernambuco, Brazil, 21Universidad Nacional de Colombia, Bogota, Colombia, 22Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, 23Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, 24Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, 25Centro de Investigación Clínica de Morelia, Morelia, Mexico, 26Hospital Ángeles del Pedregal, Mexico, Mexico, 27Rheumatology, Centro Medico ABC, Mexico, Mexico, 28Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 29Hospital General de Occidente, Guadalajara, Mexico, 30Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, 31Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), 32Universidad Peruana Cayetano Heredia, Lima, Peru, 33Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…
  • Abstract Number: 463 • 2018 ACR/ARHP Annual Meeting

    Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis

    Pooja Patel1, Marietta M. De Guzman1, Joseph Maliakkal2, Michelle Rheault3, David Selewski4, Katherine Twombley5, Jason Misurac6, Cheryl Tran7, Alexandru Constantinescu8, Ali Mirza Onder9, Meredith Seamon10, Vaishali Singh11, Cynthia Pan11, Joseph Flynn12, Abiodun Omoloja13, William Smoyer14, Guillermo Hidalgo15 and Scott E. Wenderfer16, 1Pediatrics-Rheumatology, Baylor College of Medicine, Houston, TX, 2Pediatrics-Renal, Saint Louis University, St. Louis, MO, 3Pediatrics-Renal, University of Minnesota, Minneapolis, MN, 4Pediatrics-Renal, University of Michigan, Ann Arbor, MI, 5Pediatrics-Renal, Medical University of South Carolina, Charleston, SC, 6Pediatrics-Renal, University of Iowa, Iowa City, IA, 7Pediatrics-Renal, Mayo Clinic, Rochester, MN, 8Pediatrics-Renal, Joe DiMaggio Children’s Hospital, Hollywood, FL, 9Pediatrics-Renal, University of Tennessee, Memphis, TN, 10Pediatrics-Renal, The University of Utah, Salt Lake, UT, 11Pediatrics-Renal, Medical College of Wisconsin, Wauwatosa, WI, 12Pediatrics-Renal, Seattle Children's Hospital, Seattle, WA, 13Pediatrics-Renal, Wright State University, Dayton, OH, 14Pediatrics-Renal, Nationwide Children’s Hospital, Columbus, OH, 15Pediatrics-Renal, East Carolina University, Greenville, NC, 16Pediatrics-Renal, Baylor College of Medicine, Houston, TX

    Background/Purpose: Outcomes for childhood-onset crescentic lupus nephritis are unclear. The revised classification system for lupus nephritis by the Renal Pathology Society clearly distinguishes between cellular,…
  • Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting

    Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis

    Genki Kidoguchi1 and Kenichiro Tokunaga2, 1General internal medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, 2Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan

    Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…
  • Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting

    Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis

    Adeeba Al-Herz1, Khulood Saleh2, Adel Al-Awadhi3, Waleed Al-Kandari2, Eman Hasan4, Aqeel Ghanem5, Yaser Ali5, Hebah Alhajeri6, Sawsan Hayat5, Ali Aldei7, Mohammad Hussain4, Ibrahim Nahar5, Fatemah Abutiban8, Ahmad Alenizi8, Khaled Mokaddem1, Ahmad Khadrawy2, Ammad Fazal2, Agaz Zaman5, Ghada Mazloum5, Youssef Bartella1, Sally Hamed1, Ramia Alsouk8 and Ahmed Al-Saber9, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Farwania Hospital, Farwania, Kuwait, 3Faculty of Medicine, Kuwait, Kuwait, 4Al-Amiri Hospital, Kuwait city, Kuwait, 5Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 6Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, 7Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, 8Rheumatology, Jahra Hospital, Jahra, Kuwait, 9Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

    Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
  • Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting

    How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives

    Clémence Gorlier1, Deborah Puyraimond-Zemmour1, Laura C. Coates2, Ana-Maria Orbai3, Uta Kiltz4, Ying Ying Leung5, Penelope Palominos6, Juan D. Cañete7, Rossana Scrivo8, Andra Rodica Balanescu9, Emmanuelle Dernis10, Sandra Tälli11, Adeline Ruyssen-Witrand12, Martin Soubrier13, Sibel Zehra Aydın14, Lihi Eder15, Inna Gaydukova16, Ennio Lubrano17, Pascal Richette18, M. Elaine Husni19, Maarten de Wit20, Josef S. Smolen21 and Laure Gossec22, 1Sorbonne Université, PARIS, France, 2University of Oxford, Oxford, United Kingdom, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 6Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, 7Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, 8Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 9Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 10Service de Rhumatologie, CH du Mans, Le Mans, France, 11East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, 12Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 13Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 14University of Ottawa, Ottawa, ON, Canada, 15Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 16North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, 17Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, 18Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, 19Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 20Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, 21Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 22Sorbonne Universités, Paris, France

    Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
  • Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting

    Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study

    Yair Molad1,2, Mohammad Egbaria3, Ariela Dortort-Lazar4,5, Elisheva Pokroy-Shapira3,5, Shirly Oren4, Yonatan Edel3,5 and Vitaly Kliminski5,6, 1Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, 2Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 3Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 4Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

    Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
  • Abstract Number: 744 • 2018 ACR/ARHP Annual Meeting

    Association of PCSK9 Serum Levels with Lipid Metabolism Dysregulation, Activity/Damage Scores and Subclinical Atherosclerosis in SLE Patients

    Hiurma Sanchez-Perez1, Juan Carlos Quevedo2, Iñigo Rua-Figueroa3, Beatriz Tejera-Segura4, De Vera-González AM5, Alejandra Gonzalez-Delgado6, Federico Díaz-González7 and Iván Ferraz-Amaro8, 1Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, 2Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, 3Division of Rheumatology, Hospital Doctor Negrín, Las Palmas, Spain, 4Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, 5Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, 6Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, 7Reumatología, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, 8Division of Rheumatology.Hospital Universitario de Canarias, Tenerife, Spain

    Background/Purpose: Cardiovascular disease is one of the major causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). SLE patients are characterized by…
  • Abstract Number: 766 • 2018 ACR/ARHP Annual Meeting

    Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis

    Laura Patricia Whittall1, Diana Gómez-Martín1, Jiram Torres-Ruíz2, Alejandro Zentella Dehesa1, Miguel Tapia-Rodríguez1 and Jorge Alcocer-Varela1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Current evidence suggests that neutrophils play an important role in the pathophysiology of lupus nephritis (LN) mainly through the secretion of type I IFN…
  • Abstract Number: 1096 • 2018 ACR/ARHP Annual Meeting

    Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus

    Laurent Chiche1, julie seguier2, stephanie gentile2, stephane burtey2, bertrand dussol2, philippe halfon3, wahiba bidaut3, elisabeth jouve2 and Noémie Jourde-Chiche4, 1Internal medicine, Hopital europeen, Marseille, France, 2aphm, marseille, France, 3hopital europeen, marseille, France, 4Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France

    Background/Purpose: SLE has important effects on health-related quality of life (HRQOL) and is not well correlated to disease activity. As most SLE patients in remission…
  • Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting

    Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis

    Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology